TY - JOUR
T1 - The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
T2 - International prospective validation and reliability trial in 402 patients
AU - Scherber, Robyn
AU - Dueck, Amylou C.
AU - Johansson, Peter
AU - Barbui, Tiziano
AU - Barosi, Giovanni
AU - Vannucchi, Alessandro M.
AU - Passamonti, Francesco
AU - Andreasson, Bjorn
AU - Ferarri, Maria L.
AU - Rambaldi, Alessandro
AU - Samuelsson, Jan
AU - Birgegard, Gunnar
AU - Tefferi, Ayalew
AU - Harrison, Claire N.
AU - Radia, Deepti
AU - Mesa, Ruben A.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/7/14
Y1 - 2011/7/14
N2 - Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.
AB - Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients'responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r > 0.5, P < .001) and highly reproducible (intraclass correlation coefficient > 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.
UR - http://www.scopus.com/inward/record.url?scp=79960437973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960437973&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-01-328955
DO - 10.1182/blood-2011-01-328955
M3 - Article
C2 - 21536863
AN - SCOPUS:79960437973
SN - 0006-4971
VL - 118
SP - 401
EP - 408
JO - Blood
JF - Blood
IS - 2
ER -